Literature DB >> 26200707

What Will It Take to Cure HIV?

Jintanat Ananworanich1.   

Abstract

Investigational strategies to attempt HIV cure or remission include very early initiation of antiretroviral therapy to limit the latent HIV reservoir and preinfection vaccination. In the setting of viral suppression, strategies include reactivation of latently infected cells (eg, through "shock" therapy with histone deacetylase inhibitors or other agents); use of broadly neutralizing antibodies, therapeutic vaccines, immunotoxins, or other immune-based therapies to kill latently infected cells; and gene editing to induce target cell resistance (eg, by eliminating the CC chemokine receptor 5 [CCR5] coreceptor). Improved ability to detect and quantify very low levels of virus is needed. This article summarizes a presentation by Jintanat Ananworanich, MD, PhD, at the IAS-USA continuing education program held in New York, New York, in October 2014.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26200707      PMCID: PMC6148935     

Source DB:  PubMed          Journal:  Top Antivir Med        ISSN: 2161-5853


  17 in total

1.  Large number of rebounding/founder HIV variants emerge from multifocal infection in lymphatic tissues after treatment interruption.

Authors:  Meghan K Rothenberger; Brandon F Keele; Stephen W Wietgrefe; Courtney V Fletcher; Gregory J Beilman; Jeffrey G Chipman; Alexander Khoruts; Jacob D Estes; Jodi Anderson; Samuel P Callisto; Thomas E Schmidt; Ann Thorkelson; Cavan Reilly; Katherine Perkey; Thomas G Reimann; Netanya S Utay; Krystelle Nganou Makamdop; Mario Stevenson; Daniel C Douek; Ashley T Haase; Timothy W Schacker
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-23       Impact factor: 11.205

Review 2.  Very early combination antiretroviral therapy in infants: prospects for cure.

Authors:  Kaitlin Rainwater-Lovett; Katherine Luzuriaga; Deborah Persaud
Journal:  Curr Opin HIV AIDS       Date:  2015-01       Impact factor: 4.283

3.  Absence of detectable HIV-1 viremia after treatment cessation in an infant.

Authors:  Deborah Persaud; Hannah Gay; Carrie Ziemniak; Ya Hui Chen; Michael Piatak; Tae-Wook Chun; Matthew Strain; Douglas Richman; Katherine Luzuriaga
Journal:  N Engl J Med       Date:  2013-10-23       Impact factor: 91.245

4.  Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation.

Authors:  Gero Hütter; Daniel Nowak; Maximilian Mossner; Susanne Ganepola; Arne Müssig; Kristina Allers; Thomas Schneider; Jörg Hofmann; Claudia Kücherer; Olga Blau; Igor W Blau; Wolf K Hofmann; Eckhard Thiel
Journal:  N Engl J Med       Date:  2009-02-12       Impact factor: 91.245

5.  Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV.

Authors:  Pablo Tebas; David Stein; Winson W Tang; Ian Frank; Shelley Q Wang; Gary Lee; S Kaye Spratt; Richard T Surosky; Martin A Giedlin; Geoff Nichol; Michael C Holmes; Philip D Gregory; Dale G Ando; Michael Kalos; Ronald G Collman; Gwendolyn Binder-Scholl; Gabriela Plesa; Wei-Ting Hwang; Bruce L Levine; Carl H June
Journal:  N Engl J Med       Date:  2014-03-06       Impact factor: 91.245

6.  Immune clearance of highly pathogenic SIV infection.

Authors:  Scott G Hansen; Michael Piatak; Abigail B Ventura; Colette M Hughes; Roxanne M Gilbride; Julia C Ford; Kelli Oswald; Rebecca Shoemaker; Yuan Li; Matthew S Lewis; Awbrey N Gilliam; Guangwu Xu; Nathan Whizin; Benjamin J Burwitz; Shannon L Planer; John M Turner; Alfred W Legasse; Michael K Axthelm; Jay A Nelson; Klaus Früh; Jonah B Sacha; Jacob D Estes; Brandon F Keele; Paul T Edlefsen; Jeffrey D Lifson; Louis J Picker
Journal:  Nature       Date:  2013-09-11       Impact factor: 49.962

7.  Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys.

Authors:  Dan H Barouch; James B Whitney; Brian Moldt; Florian Klein; Thiago Y Oliveira; Jinyan Liu; Kathryn E Stephenson; Hui-Wen Chang; Karthik Shekhar; Sanjana Gupta; Joseph P Nkolola; Michael S Seaman; Kaitlin M Smith; Erica N Borducchi; Crystal Cabral; Jeffrey Y Smith; Stephen Blackmore; Srisowmya Sanisetty; James R Perry; Matthew Beck; Mark G Lewis; William Rinaldi; Arup K Chakraborty; Pascal Poignard; Michel C Nussenzweig; Dennis R Burton
Journal:  Nature       Date:  2013-10-30       Impact factor: 49.962

8.  Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys.

Authors:  James B Whitney; Alison L Hill; Srisowmya Sanisetty; Pablo Penaloza-MacMaster; Jinyan Liu; Mayuri Shetty; Lily Parenteau; Crystal Cabral; Jennifer Shields; Stephen Blackmore; Jeffrey Y Smith; Amanda L Brinkman; Lauren E Peter; Sheeba I Mathew; Kaitlin M Smith; Erica N Borducchi; Daniel I S Rosenbloom; Mark G Lewis; Jillian Hattersley; Bei Li; Joseph Hesselgesser; Romas Geleziunas; Merlin L Robb; Jerome H Kim; Nelson L Michael; Dan H Barouch
Journal:  Nature       Date:  2014-07-20       Impact factor: 49.962

9.  HIV cure research: a formidable challenge.

Authors:  Jintanat Ananworanich; Anthony S Fauci
Journal:  J Virus Erad       Date:  2015-01-01

10.  Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure.

Authors:  Ya-Chi Ho; Liang Shan; Nina N Hosmane; Jeffrey Wang; Sarah B Laskey; Daniel I S Rosenbloom; Jun Lai; Joel N Blankson; Janet D Siliciano; Robert F Siliciano
Journal:  Cell       Date:  2013-10-24       Impact factor: 41.582

View more
  6 in total

1.  Development of NanoART for HIV Treatment: Minding the Cytochrome P450 (CYP) Enzymes.

Authors:  Narasimha M Midde; Santosh Kumar
Journal:  J Pers Nanomed       Date:  2015-09-10

2.  Splicing Factor 3B Subunit 1 Interacts with HIV Tat and Plays a Role in Viral Transcription and Reactivation from Latency.

Authors:  George B Kyei; Shanshan Meng; Rashmi Ramani; Austin Niu; Chandraiah Lagisetti; Thomas R Webb; Lee Ratner
Journal:  mBio       Date:  2018-11-06       Impact factor: 7.867

3.  The Dual-Specificity Kinase DYRK1A Modulates the Levels of Cyclin L2 To Control HIV Replication in Macrophages.

Authors:  Javan K Kisaka; Lee Ratner; George B Kyei
Journal:  J Virol       Date:  2020-02-28       Impact factor: 5.103

4.  Leveraging antigenic seniority for maternal vaccination to prevent mother-to-child transmission of HIV-1.

Authors:  Ashley N Nelson; Maria Dennis; Jesse F Mangold; Katherine Li; Pooja T Saha; Kenneth Cronin; Kaitlyn A Cross; Amit Kumar; Riley J Mangan; George M Shaw; Katharine J Bar; Barton Haynes; Anthony M Moody; S Munir Alam; Justin Pollara; Michael G Hudgens; Koen K A Van Rompay; Kristina De Paris; Sallie R Permar
Journal:  NPJ Vaccines       Date:  2022-07-30       Impact factor: 9.399

Review 5.  Lessons Learned From Failures and Success Stories of HIV Breakthroughs: Are We Getting Closer to an HIV Cure?

Authors:  V Kalidasan; Kumitaa Theva Das
Journal:  Front Microbiol       Date:  2020-01-31       Impact factor: 5.640

6.  Immediate start of antiretroviral, why not?

Authors:  Elaine Monteiro Matsuda; Luana Portes Ozório Coelho; Cintia Mayumi Ahagon; Ivana Barros Campos; Luís Fernando de Macedo Brígido
Journal:  Braz J Infect Dis       Date:  2018-06-22       Impact factor: 3.257

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.